RxDoctor Payments Data

Raymond Fernandez, MD

Cardiovascular Disease · Albertville, ALNPI 1699774141

Payments from drug & device makers

$2,992in general payments, 2019–2025

Across 168 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$914
  • Novartis$520
  • Merck$318
  • Irhythm Technologies, Inc.$199
  • AstraZeneca$186
  • Amgen$167
  • plus $688 from 16 others

What the payments were for

  • Food & beverage$2,979100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,992 in reported general payments places this provider in the 45th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$254,170
Medicare patients
398
Services billed
3,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban618$477,914
EntrestoSacubitril/Valsartan153$124,874
XareltoRivaroxaban65$63,977
OzempicSemaglutide54$53,361
FarxigaDapagliflozin Propanediol57$39,512
JardianceEmpagliflozin61$36,273
Repatha SureclickEvolocumab27$14,462
Ezetimibe603$13,122
BrilintaTicagrelor27$11,513
Metoprolol Succinate681$10,118
Clonidine71$8,127
Ranolazine ErRanolazine99$7,211
Nifedipine ErNifedipine290$4,782
Losartan Potassium280$3,812
Atorvastatin Calcium333$3,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$477,914618 claims
NovartisEntresto$520$124,874153 claims
Johnson & JohnsonXarelto$29$63,97765 claims
Novo NordiskOzempic$115$53,36154 claims
AstraZenecaFarxiga, Brilinta$186$51,02584 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Albertville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →